查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198195

去腎神經設備市場——增長、趨勢和預測 (2023-2028)

Renal Denervation Devices Market - Growth, Trends, and Forecast (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，腎臟去神經設備市場預計將以 36.89% 的複合年增長率增長。

主要亮點

  • COVID-19 大流行顯著減少了醫院和醫療保健服務，從而影響了腎臟去神經設備市場。 在 COVID-19 流行期間，許多醫療設備製造商由於缺乏資源和資金而推遲或延遲設備發布，這對去腎神經設備市場產生了負面影響。 然而，儘管存在這些挫折，大流行期間高血壓和大量飲酒的上升可能有助於市場在短期內復蘇。 例如，根據國家酒精濫用和酒精中毒研究所的數據，2020 年 1 月至 2020 年 8 月期間，美國 15 個州的酒精銷售量同比增長 4%，增加了患高血壓和去腎神經裝置的風險. 可能會刺激使用 因此，由於產品銷量增加、新產品發布以及與高血壓相關的健康問題增加等因素，預計未來幾年所研究的市場將出現增長。
  • 高血壓患病率上升和治療的長期影響是推動去腎神經設備市場增長的主要因素。 近年來，高血壓的患病率明顯上升。 根據世界衛生組織 2021 年 8 月的更新，全球約有 12.8 億 30-79 歲的人受到高血壓的影響。 預計在預測期內，高血壓病例數量的增加將產生對去腎神經設備的需求。 高血壓患病率上升的主要原因是人口老齡化、高鈉低鉀攝入、肥胖增加、低收入和中等收入國家飲酒量增加、體力活動減少、飲食均衡等。在。
  • 此外，兒童和成人肥胖等其他慢性病患病率上升也將在整個預測期內推動去腎神經設備市場的增長。 據世界衛生組織統計，到 2021 年，將有超過 3900 萬五歲以下兒童超重。 肥胖人群的高瘦素水平可誘導下丘腦血管增生，從而導致高血壓，因此這種情況可能會推高對腎神經去神經治療的需求。 此外，增加經常飲酒會導致高血壓，因為酒精會刺激腎上腺釋放腎上腺素，從而導致心率、心輸出量和收縮壓增加，這將進一步推動市場的增長。
  • 此外，與去腎神經設備相關的臨床研究和研發的增加以及去腎設備的長期效益預計將推動市場增長。 例如，根據 2022 年 4 月發表在《自然》雜誌上的一篇論文，泰國 80% 以上的頑固性高血壓患者經歷了腎神經去神經支配的結果，這些結果在長期隨訪中得以維持，沒有乾預相關的副作用。據說它已完成。
  • 因此，由於高血壓患病率上升以及腎去神經設備提供的長期益處，預計所研究的市場在預測期內會出現增長。 然而，預計在預測期內，腎去神經設備的嚴格審批程序、報銷制度和痛苦的程序將抑制市場增長。

去腎神經設備的市場趨勢

基於超聲的細分市場預計在預測期內增長最快

基於超聲的腎去神經支配裝置是一種微創手術，它使用超聲消融腎動脈壁中的神經。 它可以阻止神經衝動傳入和傳出腎臟並降低血壓。 由於高血壓患病率上升和對基於超聲的去腎神經設備的需求增加等因素，基於超聲的去腎神經設備有望顯示市場增長。 例如，根據世界衛生組織 2022 年 6 月的更新，估計印度至少有四分之一的成年人患有高血壓，其中只有約 12% 的人血壓得到控制。 這種高血壓與高膽固醇水平有關，其發病率的增加可能會加強對基於超聲的去腎神經設備的產品需求。

此外，預計在預測期內，對超聲腎去神經支配設備的研究越來越多，將推動市場增長。 例如，根據 2021 年 10 月發表在 PubMed 上的一篇論文，超聲 In REQUIRE 試驗旨在評估日本和韓國頑固性高血壓患者接受去腎神經術的降壓效果。 此類試驗的有利結果可能會導致新的治療選擇，並在預測期內提高該部門的增長率。

創新產品發布和研究合作是主要市場參與者在該領域採取的一些舉措，以提高其在全球市場的影響力。 例如，2020 年 12 月，ReCor Medical Inc. 因其革命性的 Paradise 超聲腎去神經系統獲得了美國 FDA 的突破性設備稱號，該系統旨在利用超聲波能量消融腎神經。。 因此，由於高血壓患病率上升、與基於超聲的腎去神經設備相關的研究活動增加以及產品批准的增加，預計研究部門在預測期內將出現市場增長。

預測期內，歐洲去腎神經設備市場有望顯著增長

由於高血壓患病率上升、技術進步不斷增加以及治療的長期影響等因素，歐洲的去腎神經設備市場可能會出現顯著增長。 例如，根據健康改善和差異辦公室的統計數據，2021 年英格蘭的高血壓患病率為 845.76 萬人。 此外，根據2021年在意大利進行的一項調查，73.6%的參與者表示他們知道自己的血壓狀況，42.3%的人被診斷為高血壓，41.4%的人正在服用降壓藥。我回答是。 此外，男性自報高血壓的患病率高於女性。 因此，高血壓發病率的增加已成為推動該地區增長的關鍵因素之一。

此外，增加研發活動以開發高效設備也是推動市場增長的主要因素。 該地區產品發布數量的增加也將有助於市場增長。 例如，2021 年 10 月，ReCor Medical Inc. 將在歐洲推出超聲波去腎神經系統，該系統可能會在德國用於治療未控制的高血壓。 因此，由於高血壓患病率上升和腎去神經設備產品批准的增加，預計歐洲在預測期內將出現增長。

去腎神經設備市場競爭對手分析

由於幾家主要參與者的存在，市場正在整合。 各大公司紛紛採取研發、併購、產品發布等多種策略來鞏固市場地位。

市場參與者包括 Abbott、Ablative Solutions、Boston Scientific Corporation、CardioSonic、Kona Medical、Medtronic PLC、Mercator MedSystems、ReCor Medical 和 Simple Surgical。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 高血壓患病率上升
    • 治療的長期效果
  • 市場製約因素
    • 痛苦的治療
    • 去腎神經設備的嚴格審批流程和報銷制度
  • 波特的五力分析
    • 新進入者的威脅
    • 消費者的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按技術
    • 基於無線電波
    • 基於超聲
    • 微輸液
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 世界其他地區

第6章競爭格局

  • 公司簡介
    • Medtronic PLC
    • Abbott Laboratories（St. Jude Medical Inc.）
    • Otsuka Holdings Co. Ltd（ReCor Medical Inc.）
    • Ablative Solutions Inc.
    • Mercator MedSystems
    • Terumo Corporation
    • Symple Surgical
    • Boston Scientific Corporation
    • SoniVie
    • Recor Medical Inc.

第7章 市場機會與今後動向

簡介目錄
Product Code: 57103

The renal denervation devices market is expected to register a CAGR of 36.89% during the forecast period.

Key Highlights

  • The outbreak of the COVID-19 pandemic impacted the renal denervation devices market as hospitals and healthcare services significantly reduced due to social distancing measures taken by countries across the world. During the COVID-19 outbreak, many medical device manufacturers either delayed or postponed the launch of their devices due to resource and fund crunch, negatively impacting the renal denervation devices market. However, despite these setbacks, rising levels of hypertension coupled with high alcohol consumption during the pandemic may contribute to the market recovery over the foreseeable future. For instance, according to the National Institute on Alcohol Abuse and Alcoholism, the quantity of alcohol sold in 15 US states rose by 4% from January to August 2020 as compared to a year earlier, which could increase the risk of hypertension and stimulate the use of renal denervation devices. Hence, the studied market is anticipated to witness growth in the coming years owing to factors such as a rise in product sales, new product launches, and an increase in hypertension-related health issues.
  • Major factors responsible for the growth of the renal denervation devices market include the rising prevalence of hypertension and the long-lasting effect of the procedure. The prevalence of hypertension has been observing a significant rise over the past few years. According to the August 2021 update from the WHO, around 1.28 billion people aged between 30 and 79 years are affected by hypertension globally. An increase in the number of cases of hypertension is expected to create demand for renal denervation devices during the forecast period. Some major reasons for an increase in the prevalence of hypertension are the increasing geriatric population, high sodium and low potassium intake, rising cases of obesity, increasing alcohol consumption in low- and middle-income countries, physical inactivity, and the lack of a balanced diet.
  • Additionally, increasing the patient pool of other chronic diseases like obesity among children and adults will power renal denervation market growth through the forecast period. As per the WHO's statistics, over 39 million children aged below 5 years were overweight in 2021. This condition is likely to push the demand for renal nerve denervation therapy, as high leptin levels in obese people can trigger the growth of blood vessels in the hypothalamus, thereby causing hypertension. A rise in the level of daily alcohol consumption will further drive the market growth, as regular drinking may lead to hypertension as it is possible that alcohol may stimulate adrenals to release adrenaline, resulting in increased heart rate, cardiac output, and systolic blood pressure.
  • Furthermore, an increase in clinical studies and research and development associated with renal denervation devices and the long-term benefits of renal denervation procedures are anticipated to drive market growth. For instance, as per the article published in April 2022 in Nature journal, more than 80% of Thai patients with resistant hypertension experienced the success of the renal nerve denervation outcome, which was sustained over a longer follow-up without any intervention-related side effects.
  • Hence, due to the rise in the prevalence of hypertension and the long-term benefits offered by renal denervation devices, the studied market is anticipated to witness growth in the studied market over the forecast period. However, stringent approval processes for renal denervation devices and reimbursement systems and painful procedures are anticipated to restrain the market growth over the forecast period.

Renal Denervation Devices Market Trends

The Ultrasound-based Segment is Expected to be the Fastest-growing Segment Over the Forecast Period

The ultrasound-based renal denervation devices are a minimally invasive procedure that uses ultrasound to ablate nerves in the wall of the renal arteries. It disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure. The ultrasound-based renal denervation devices are anticipated to witness growth in the market owing to the factors such as a rise in the prevalence of hypertension and an increase in demand for ultrasound-based renal denervation devices. For instance, as per the June 2022 update from WHO, it is estimated that at least one in four adults in India has hypertension, and only about 12% of them have their blood pressure under control. Such high blood pressure is linked with high cholesterol levels, and its growing incidence could bolster product demand for ultrasound-based renal denervation devices.

Furthermore, a rise in research studies of ultrasound-based renal denervation devices is anticipated to boost market growth over the forecast period. For instance, as per an article published in October 2021 by PubMed, an ultrasound In REsistant hypertension (REQUIRE) trial was designed to assess the BP-lowering efficacy of renal denervation in patients with resistant hypertension from Japan and South Korea. Thus, postive outcome of such studies may results into new treatment option, thereby increasing the segmental growth over the forecast period.

Innovative product launches and collaborations are some of the initiatives being undertaken in this segment by key market players to reinforce their presence in the global market. For instance, in December 2020, ReCor Medical Inc. received the US FDA's Breakthrough Device Designation for its innovative Paradise Ultrasound Renal Denervation System, designed to ablate the renal nerve using ultrasound energy. Hence, due to the rise in the prevalence of hypertension, the increase in research activities associated with ultrasound-based renal denervation devices and rise in product approvals, the studied segment is anticipated to witness growth in the market over the forecast period.

Europe is Anticipated to Witness a Significant Growth in the Renal Denervation Devices Market Over the Forecast Period

Europe is likely to witness significant growth in the renal denervation devices market owing to the factors such as a rise in the prevalence of hypertension, an increase in technological advancements, and the long-lasting effect of the procedure. For instance, as per the Office of Health Improvement and Disparities statistics, the prevalence of hypertension in England was 8,457,600 in 2021. Moreover, as per a Survey conducted in 2021 in Italy, 73.6% of participants reported being aware of their BP status, 42.3% reported a diagnosis of hypertension, and 41.4% were taking antihypertensive medications. The prevalence of self-reported hypertension was also greater in men than women. Thus, increasing the incidence of hypertension is one of the key factors responsible for the region's growth.

Furthermore, the major factor driving the market's growth is growing R&D activities to develop efficient devices. The rise in the number of product launches in the region will also contribute to the market's growth. For instance, in October 2021, ReCor Medical Inc. launched the ultrasound renal denervation system in Europe, which is likely to be used to treat uncontrolled hypertension in Germany. Hence, due to the rise in the prevalence of hypertension and the increase in product approvals for renal denervation devices, Europe is anticipated to witness growth over the forecast period.

Renal Denervation Devices Market Competitor Analysis

The market is consolidated due to the presence of some major market players. Various strategies, such as R&D, M&A, and product launch, are being adopted by key companies to strengthen their market position.

Some of the market players are Abbott, Ablative Solutions, Boston Scientific Corporation, CardioSonic, Kona Medical, Medtronic PLC, Mercator MedSystems, ReCor Medical, and Symple Surgical.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Hypertension
    • 4.2.2 Long Lasting Effect of the Procedure
  • 4.3 Market Restraints
    • 4.3.1 Painful Procedure
    • 4.3.2 Stringent Approval Process for Renal Denervation Devices and Reimbursement Systems
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Technology
    • 5.1.1 Radiofrequency-based
    • 5.1.2 Ultrasound-based
    • 5.1.3 Micro-infusion-based
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic PLC
    • 6.1.2 Abbott Laboratories (St. Jude Medical Inc.)
    • 6.1.3 Otsuka Holdings Co. Ltd (ReCor Medical Inc.)
    • 6.1.4 Ablative Solutions Inc.
    • 6.1.5 Mercator MedSystems
    • 6.1.6 Terumo Corporation
    • 6.1.7 Symple Surgical
    • 6.1.8 Boston Scientific Corporation
    • 6.1.9 SoniVie
    • 6.1.10 Recor Medical Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS